Several companies have adjusted their earnings-per-share forecasts for the year from what they had issued when they announced fourth-quarter 2019 earnings or expect to see negative impacts on sales of certain drug products, while others reaffirmed guidances.

LEAVE A REPLY

Please enter your comment!
Please enter your name here